Literature DB >> 23557919

Risk factors for both recurrence and survival in patients with pathological stage I non-small-cell lung cancer.

Yoshiki Kozu1, Tomohiro Maniwa, Shoji Takahashi, Mitsuhiro Isaka, Yasuhisa Ohde, Takashi Nakajima.   

Abstract

OBJECTIVES: Even after curative resection, a significant fraction of patients with stage I non-small-cell lung cancer (NSCLC) die primarily because of systemic relapse. The purpose of the present study was to investigate the risk factors for both recurrence and poor survival in patients with pathological (p-) stage I NSCLC.
METHODS: We retrospectively reviewed 467 consecutive patients from a single institution with completely resected p-stage I NSCLC. Patients with multiple lung tumours or malignancies from other organs and those who had undergone preoperative therapies were excluded. The correlation between clinicopathological factors and surgical outcomes, including disease-free survival (DFS) and overall survival (OS), was analysed. The clinicopathological factors examined were age, gender, smoking history, serum carcinoembryonic antigen (CEA) levels, serum cytokeratin 19 fragment levels, surgical procedure, tumour histology, p-stage, angiolymphatic invasion and differentiation grade.
RESULTS: The 5-year DFS and OS rates of the total study population were 91.4 and 92.8%, respectively. Multivariate analysis results indicated that high serum CEA levels (>5.0 ng/ml) and p-stage IB were independent factors for recurrence, whereas older age (>70 years), high serum CEA levels and p-stage IB were independent factors for poor survival. The risks of recurrence and death in patients with both high serum CEA levels and p-stage IB was 10.3 and 5.2 times higher than those observed in patients with both normal serum CEA levels and p-stage IA, respectively.
CONCLUSIONS: High serum CEA levels and p-stage IB were independent factors for both recurrence and poor survival in p-stage I NSCLC patients.

Entities:  

Keywords:  Carcinoembryonic antigen; Non-small-cell lung cancer; Pathological stage; Recurrence and poor survival; Risk factor

Mesh:

Substances:

Year:  2013        PMID: 23557919     DOI: 10.1093/ejcts/ezt192

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  12 in total

1.  Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.

Authors:  Y-L Hsu; J-Y Hung; S-H Chou; M-S Huang; M-J Tsai; Y-S Lin; S-Y Chiang; Y-W Ho; C-Y Wu; P-L Kuo
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

2.  Evaluation of lung cancer by enhanced dual-energy CT: association between three-dimensional iodine concentration and tumour differentiation.

Authors:  Shingo Iwano; Rintaro Ito; Hiroyasu Umakoshi; Shinji Ito; Shinji Naganawa
Journal:  Br J Radiol       Date:  2015-09-02       Impact factor: 3.039

3.  Log odds of positive lymph nodes are superior to other measures for evaluating the prognosis of non-small cell lung cancer.

Authors:  Peng Lv; Gang Chen; Peng Zhang
Journal:  Thorac Cancer       Date:  2014-10-23       Impact factor: 3.500

4.  Repression of YAP by NCTD disrupts NSCLC progression.

Authors:  Jiwei Guo; Yan Wu; Lijuan Yang; Jing Du; Kaikai Gong; Weiwei Chen; Juanjuan Dai; XueLin Li; Sichuan Xi
Journal:  Oncotarget       Date:  2017-01-10

Review 5.  Optimal delivery of follow-up care following pulmonary lobectomy for lung cancer.

Authors:  Ying-Yi Chen; Tsai-Wang Huang; Hung Chang; Shih-Chun Lee
Journal:  Lung Cancer (Auckl)       Date:  2016-03-30

6.  Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non-small cell lung cancer patients.

Authors:  Chia-Hsin Liu; Yi-Jen Peng; Hong-Hau Wang; Ying-Chieh Chen; Chen-Liang Tsai; Chih-Feng Chian; Tsai-Wang Huang
Journal:  Thorac Cancer       Date:  2015-02-27       Impact factor: 3.500

7.  Evaluation of locoregional invasiveness of small-sized non-small cell lung cancers by enhanced dual-energy computed tomography.

Authors:  Hironori Shimamoto; Shingo Iwano; Hiroyasu Umakoshi; Koji Kawaguchi; Shinji Naganawa
Journal:  Cancer Imaging       Date:  2016-07-26       Impact factor: 3.909

8.  The role of Thyroid Transcription Factor-1 and Tumor differentiation in Resected Lung Adenocarcinoma.

Authors:  Tsai-Wang Huang; Ke- Feng Lin; Chien-Hsing Lee; Hung Chang; Shih-Chun Lee; Yi-Shing Shieh
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

9.  Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression.

Authors:  Jiwei Guo; Yan Wu; Jing Du; Lijuan Yang; Weiwei Chen; Kaikai Gong; Juanjuan Dai; Shuang Miao; Dan Jin; Sichuan Xi
Journal:  Oncogenesis       Date:  2018-06-13       Impact factor: 7.485

10.  Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer.

Authors:  Abby White; Suden Kucukak; Daniel N Lee; Raphael Bueno; Michael Jaklitsch; Steven Mentzer; David Sugarbaker; Jon Wee; Scott J Swanson
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.